TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. III
5. TTEC
6. DAL
7. AWK
8. SPCX
9. KWM
10. RAY-A

Go back to TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
(NASDAQ: RNAZ) Delayed: 4.70 -0.65 (12.15%)
Previous Close $5.35    52 Week High $ 
Open $5.28    52 Week Low $ 
Day High $5.45    P/E N/A 
Day Low $4.70    EPS $ 
Volume 31,670